| Entry Id | Entry Title | Agency | Judge Username | Judge Email | Judge Date | Visual quality: Do the photography and/or the illustrations add intrigue or stopping power to the message? | Art direction: Does the art element make me want to look at the piece? | Message quality: Does the copy clearly communicate the intended message? | Overall effectiveness: How well did the piece accomplish the desired results based on the objectives and results described in the applicant’s submission? | Total Score |
|---|---|---|---|---|---|---|---|---|---|---|
| 166 | Peritoneal dialysis ‘I could have stayed home’ campaign | Lemieux Bédard | anthony.turow | [email protected] | May 11, 2022 | 2 | 2 | 4 | 5 | 13 |
| 166 | Peritoneal dialysis ‘I could have stayed home’ campaign | Lemieux Bédard | jennifer.dilworth | [email protected] | May 9, 2022 | 4 | 3 | 3 | 7 | 17 |
| 166 | Peritoneal dialysis ‘I could have stayed home’ campaign | Lemieux Bédard | kris.rieger | [email protected] | May 18, 2022 | 3 | 3 | 4 | 7 | 17 |
| 166 | Peritoneal dialysis ‘I could have stayed home’ campaign | Lemieux Bédard | mazen.baradhy | [email protected] | May 9, 2022 | 3 | 3 | 4 | 3 | 13 |
| 166 | Peritoneal dialysis ‘I could have stayed home’ campaign | Lemieux Bédard | patrick.massad | [email protected] | May 7, 2022 | 4 | 4 | 5 | 9 | 22 |
| 15 | PersonalizeHemA App | Renegade Healthcare/Takeda Canada Inc. | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 16 | PersonalizeHemA Digital Marketing Campaign | Renegade Healthcare/Takeda Canada Inc. | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 16 | PersonalizeHemA Digital Marketing Campaign | Renegade Healthcare/Takeda Canada Inc. | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 14 | PersonalizeHemA Website | Renegade Healthcare/Takeda Canada Inc. | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 143 | PLACEHOLDER Campaign | Lampyon PLACEHOLDER | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 143 | PLACEHOLDER Campaign | Lampyon PLACEHOLDER | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 143 | PLACEHOLDER Campaign | Lampyon PLACEHOLDER | jennifer.dilworth | [email protected] | May 9, 2022 | 1 | 1 | 1 | 1 | 4 |
| 143 | PLACEHOLDER Campaign | Lampyon PLACEHOLDER | mazen.baradhy | [email protected] | May 9, 2022 | 1 | 1 | 1 | 1 | 4 |
| 144 | PLACEHOLDER2 | Lampyon PLACEHOLDER2 | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 144 | PLACEHOLDER2 | Lampyon PLACEHOLDER2 | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 144 | PLACEHOLDER2 | Lampyon PLACEHOLDER2 | jennifer.dilworth | [email protected] | May 9, 2022 | 1 | 1 | 1 | 1 | 4 |
| 144 | PLACEHOLDER2 | Lampyon PLACEHOLDER2 | mazen.baradhy | [email protected] | May 9, 2022 | 1 | 1 | 1 | 1 | 4 |
| 151 | POO TABOO Campaign | Toc Toc Communications | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 151 | POO TABOO Campaign | Toc Toc Communications | anthony.turow | [email protected] | May 11, 2022 | 2 | 3 | 4 | 6 | 15 |
| 151 | POO TABOO Campaign | Toc Toc Communications | jennifer.dilworth | [email protected] | May 9, 2022 | 4 | 4 | 4 | 8 | 20 |
| 151 | POO TABOO Campaign | Toc Toc Communications | kris.rieger | [email protected] | May 18, 2022 | 3 | 3 | 3 | 6 | 15 |
| 151 | POO TABOO Campaign | Toc Toc Communications | mazen.baradhy | [email protected] | May 9, 2022 | 4 | 4 | 4 | 4 | 16 |
| 151 | POO TABOO Campaign | Toc Toc Communications | patrick.massad | [email protected] | May 7, 2022 | 5 | 5 | 4 | 7 | 21 |
| 149 | PROPECIA HCP Mailler | Toc Toc Communications | May 8, 2022 | 4 | 4 | 5 | 9 | 22 | ||
| 149 | PROPECIA HCP Mailler | Toc Toc Communications | anthony.turow | [email protected] | May 11, 2022 | 4 | 4 | 4 | 8 | 20 |
| 149 | PROPECIA HCP Mailler | Toc Toc Communications | mazen.baradhy | [email protected] | May 9, 2022 | 2 | 2 | 3 | 5 | 12 |
| 148 | PROPECIA Starter Kit | Toc Toc Communications | May 8, 2022 | 4 | 4 | 5 | 9 | 22 | ||
| 148 | PROPECIA Starter Kit | Toc Toc Communications | anthony.turow | [email protected] | May 11, 2022 | 2 | 2 | 2 | 4 | 10 |
| 148 | PROPECIA Starter Kit | Toc Toc Communications | jennifer.dilworth | [email protected] | May 9, 2022 | 3 | 3 | 3 | 6 | 15 |
| 148 | PROPECIA Starter Kit | Toc Toc Communications | kris.rieger | [email protected] | May 18, 2022 | 3 | 2 | 3 | 7 | 15 |
| 148 | PROPECIA Starter Kit | Toc Toc Communications | mazen.baradhy | [email protected] | May 9, 2022 | 2 | 2 | 2 | 4 | 10 |
| 13 | See the Possibilities Digital | CPC Healthcare | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 12 | See the Possibilities Print | CPC Healthcare | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 25 | Senior Brand Manager | Trois Prime / Bausch Health | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 18 | Showing on the inside | Lemieux Bédard Communications/Roche Diagnostics | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 10 | The Biktarvy Pill Campaign | CPC Healthcare | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 10 | The Biktarvy Pill Campaign | CPC Healthcare | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 17 | The New Pap | Lemieux Bédard Communications/Roche Diagnostics | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 17 | The New Pap | Lemieux Bédard Communications/Roche Diagnostics | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 155 | Understanding Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon | Bayer Canada, Canadian Health | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 155 | Understanding Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon | Bayer Canada, Canadian Health | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 155 | Understanding Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon | Bayer Canada, Canadian Health | anthony.turow | [email protected] | May 11, 2022 | 1 | 1 | 1 | 1 | 4 |
| 155 | Understanding Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon | Bayer Canada, Canadian Health | jennifer.dilworth | [email protected] | May 9, 2022 | 2 | 2 | 4 | 5 | 13 |
| 155 | Understanding Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon | Bayer Canada, Canadian Health | kris.rieger | [email protected] | May 18, 2022 | 3 | 3 | 4 | 8 | 18 |
| 155 | Understanding Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon | Bayer Canada, Canadian Health | mazen.baradhy | [email protected] | May 9, 2022 | 1 | 1 | 1 | 1 | 4 |
| 155 | Understanding Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon | Bayer Canada, Canadian Health | patrick.massad | [email protected] | May 7, 2022 | 3 | 3 | 4 | 7 | 17 |
| 157 | Unexplained Shortness of Breath | The Adpharm Inc. | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 157 | Unexplained Shortness of Breath | The Adpharm Inc. | anthony.turow | [email protected] | May 11, 2022 | 4 | 4 | 4 | 8 | 20 |
| 157 | Unexplained Shortness of Breath | The Adpharm Inc. | jennifer.dilworth | [email protected] | May 9, 2022 | 4 | 4 | 5 | 9 | 22 |
| 157 | Unexplained Shortness of Breath | The Adpharm Inc. | mazen.baradhy | [email protected] | May 9, 2022 | 5 | 5 | 5 | 9 | 24 |
| 157 | Unexplained Shortness of Breath | The Adpharm Inc. | patrick.massad | [email protected] | May 7, 2022 | 4 | 4 | 4 | 8 | 20 |
| 11 | XTANDI Baseball Campaign | CPC Healthcare | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 160 | You are not you COPD | McCann Health | July 30, 2022 | 5 | 5 | 5 | 10 | 25 | ||
| 160 | You are not you COPD | McCann Health | anthony.turow | [email protected] | May 11, 2022 | 2 | 3 | 2 | 6 | 13 |
| 160 | You are not you COPD | McCann Health | jennifer.dilworth | [email protected] | May 9, 2022 | 5 | 5 | 5 | 9 | 24 |
| 160 | You are not you COPD | McCann Health | kris.rieger | [email protected] | May 18, 2022 | 3 | 3 | 3 | 6 | 15 |
| 160 | You are not you COPD | McCann Health | mazen.baradhy | [email protected] | May 9, 2022 | 3 | 3 | 4 | 3 | 13 |
| 160 | You are not you COPD | McCann Health | patrick.massad | [email protected] | May 7, 2022 | 4 | 4 | 4 | 9 | 21 |
| 147 | ZAXINE Print Ad | Toc Toc Communications | May 8, 2022 | 5 | 4 | 5 | 9 | 23 | ||
| 147 | ZAXINE Print Ad | Toc Toc Communications | anthony.turow | [email protected] | May 11, 2022 | 4 | 4 | 4 | 8 | 20 |
| 147 | ZAXINE Print Ad | Toc Toc Communications | jennifer.dilworth | [email protected] | May 9, 2022 | 5 | 4 | 3 | 8 | 20 |
| 147 | ZAXINE Print Ad | Toc Toc Communications | kris.rieger | [email protected] | May 18, 2022 | 2 | 2 | 4 | 7 | 15 |
| 147 | ZAXINE Print Ad | Toc Toc Communications | mazen.baradhy | [email protected] | May 9, 2022 | 4 | 5 | 4 | 8 | 21 |
| Entry Id | Entry Title | Agency | Judge Username | Judge Email | Judge Date | Visual quality: Do the photography and/or the illustrations add intrigue or stopping power to the message? | Art direction: Does the art element make me want to look at the piece? | Message quality: Does the copy clearly communicate the intended message? | Overall effectiveness: How well did the piece accomplish the desired results based on the objectives and results described in the applicant’s submission? | Total Score |
Join our Mailing list!
Get all latest news about our programs, subscribe to our newsletter!